HighMark Wealth Management LLC Has $155,000 Stake in Prothena Co. plc (NASDAQ:PRTA)

HighMark Wealth Management LLC reduced its position in shares of Prothena Co. plc (NASDAQ:PRTA) by 32.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 11,168 shares of the biotechnology company’s stock after selling 5,334 shares during the period. HighMark Wealth Management LLC’s holdings in Prothena were worth $155,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in PRTA. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Prothena by 10.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 11,409 shares of the biotechnology company’s stock worth $158,000 after buying an additional 1,065 shares in the last quarter. Chicago Partners Investment Group LLC acquired a new stake in Prothena in the 4th quarter worth about $159,000. Intech Investment Management LLC acquired a new stake in Prothena in the 3rd quarter worth about $210,000. XTX Topco Ltd bought a new stake in Prothena in the 3rd quarter valued at about $260,000. Finally, Orion Portfolio Solutions LLC grew its position in shares of Prothena by 4.4% during the 3rd quarter. Orion Portfolio Solutions LLC now owns 17,531 shares of the biotechnology company’s stock worth $293,000 after purchasing an additional 739 shares in the last quarter. 97.08% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on PRTA. StockNews.com downgraded shares of Prothena from a “hold” rating to a “sell” rating in a research report on Tuesday, November 19th. Bank of America cut their target price on Prothena from $26.00 to $22.00 and set a “neutral” rating for the company in a research report on Thursday, December 19th. Oppenheimer raised their price target on Prothena from $58.00 to $62.00 and gave the stock an “outperform” rating in a research report on Friday, February 7th. HC Wainwright reaffirmed a “buy” rating and set a $48.00 price objective (down previously from $84.00) on shares of Prothena in a research report on Friday, December 20th. Finally, Chardan Capital started coverage on shares of Prothena in a research note on Friday, December 20th. They set a “buy” rating and a $40.00 price objective on the stock. One research analyst has rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $46.50.

Prothena Price Performance

Shares of NASDAQ PRTA opened at $14.17 on Tuesday. Prothena Co. plc has a 12 month low of $11.70 and a 12 month high of $31.03. The stock has a 50-day moving average price of $14.24 and a two-hundred day moving average price of $16.90.

Prothena Profile

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson’s disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer’s disease.